… Regola a e , Francesco Castelli e h , Franco Franceschini a e , Paolo Airò a , Chiara
Bazzani a , Eva-Andrea Beindorf i , Marialma Berlendis j , Michela Bezzi k , Nicola Bossini l , …

… plasma or serum levels were unlikely to achieve the concentration shown to inhibit SARS-CoV-2
in vitro (average target 0.48 mg/L as opposed to the antiviral target of 4/1 mg/L) [113]. …

… Andreoli’s work was supported by a research grant financed by an agreement between the
Government of Lombardy and the University of Brescia. Dr. Chighizola’s work was supported …

The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …

Objective To develop new antiphospholipid syndrome (APS) classification criteria with high
specificity for use in observational studies and trials, jointly supported by the American …

Objectives Develop recommendations for women9s health issues and family planning in
systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). Methods …

Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation
and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared …

Current classification criteria for definite Antiphospholipid Syndrome (APS) require the use
of three laboratory assays to detect antiphospholipid antibodies (aCL, anti-β2GPI and LA) in …

Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound
hypercoagulable state and often develop coagulopathy which leads to organ failure and …

… The non-survivors, as compared to survivors, had the lowest platelets counts with WMD -48
× 10 9 /L (95% CI -57 to −39 × 10 9 /L). The prevalence of thrombocytopenia was reported in …